The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports

Chen in Q2 2024: It's Silver, Again, as Precious Metal Breaks Out

  ()
After being bullish on silver for at least the last year, asset manager Chen Lin feels a little vindicated by the precious metal's recent two-year high.
Tags: Biotechnology / PharmaceuticalsGoldOil & Gas - Exploration & ProductionSilver

Biotech's Lawsuit With Eli Lilly Might Catalyze Stock

  ()
Nektar Therapeutics has commenced a Phase 2b clinical trial evaluating its lead product candidate rezpegaldesleukin in patients with severe to very severe alopecia areata. In other news, Nektar has a lawsuit pending against Eli Lilly & Co. Read on to see what two experts have to say about this biotech stock.
Tags:  Biotechnology / Pharmaceuticals

Biotech Stocks Break Out

Contributed Opinion
  ()
Ron Struthers of Struthers Stock Report shares that the S&P Biotech SPDR is over 60% this year and trading around $100 a share. He also details how well he has down, buying under valued cash-rich biotechs in 2023, and shares one stock he believes it worth looking into.
Tags:  Biotechnology / PharmaceuticalsMedical Devices

Biotech Co.'s Target Price Significantly Higher Than Current

Research Report
  ()
Biofrontera Inc. is currently trading at US$1.26, but has a target price of US$26, according to a Roth MKM research note.
Tags:  Biotechnology / Pharmaceuticals

Is This Pharma Set To Break Out After COPD Drug Approval?

  ()
Clinical-stage biopharmaceutical company Verona Pharma Plc is looking toward a pivotal year as its new chronic obstructive pulmonary disease (COPD) drug ensifentrine nears possible approval by the FDA. At least two research companies have named it a top pick for 2024.
Tags:  Biotechnology / Pharmaceuticals

This Biotech Is a Potential Disruptor, Expert Says

Contributed Opinion
  ()
Chris Temple of The National Investor shares why he believes BetterLife Pharma Inc. is an Immediate Buy.
Tags:  Biotechnology / Pharmaceuticals

NY Biotech Has Potentially Game Changing Anxiety Therapy

Research Report
  ()
Mind Medicine (MindMed) Inc. recently announced positive results from its Phase 2b trial of MM120 in generalized anxiety disorder, according to a Roth MKM research note.
Tags:  Biotechnology / Pharmaceuticals

Alt-Pharma VC adds 7% Stake in Testing Strip Firm

  ()
Alt pharma is hot these days, and few companies are coming in hotter than Safe Supply Streaming Co. Ltd., which just secured a 7% stake in a leading medical test company to expand its functional portfolio.
Tags:  Biotechnology / Pharmaceuticals

Cash Rich Biotech Could Win a Lawsuit With Lilly, Expert Says

Contributed Opinion
  ()
Ron Struthers explains how the cash value of this biotech is about $1.68/share and the stock is selling at around -58% discount to cash value. He also discusses a recent lawsuit with Eli Lilly.
Tags:  Biotechnology / Pharmaceuticals

Drug Reformer Subsidiary Inspected for Dealer License

  ()
In a "transformative moment" for the company, a Safe Supply Streaming Co. Ltd. subsidiary has undergone an official inspection by Health Canada to acquire a dealer license to produce, distribute, and export controlled substances.
Tags:  Biotechnology / PharmaceuticalsCannabis

Leadership Cuts Won't Slow This Biotech

Research Report
  ()
While three executive officers have been cut from Kronos Bio Inc., it is still a Buy, according to an H.C. Wainwright & Co. report.
Tags:  Biotechnology / Pharmaceuticals

Pharma Co. Primed for Future Business

Research Report
  ()
Analysts at Research Capital believe that Knight Therapeutics Inc. is primed to conduct future business development.
Tags:  Biotechnology / Pharmaceuticals

Healthcare Co. Exceeds Expectations in Performance

Research Report
  ()
Sensus Healthcare Inc. released fourth-quarter financials that surpassed expectations, according to an H.C. Wainwright & Co. research note.
Tags:  Healthcare ServicesBiotechnology / Pharmaceuticals

Money Manager: The Year of Small Caps?

  ()
The president and chief executive officer of Toronto-based AlphaNorth Asset Management says his positive outlook on 2024 has not changed. In fact, it could be a great year for small caps.
Tags:  Cobalt / Lithium / ManganeseBiotechnology / PharmaceuticalsSilverBattery MetalsGoldTechnologyAlternative - Cleantech

Big Pharma's Looming Patents May Benefit One Biotech

  ()
Pharma stocks took big hits in recent years as many of its largest companies saw a looming "patent cliff" that could dry out profits from their big cash-cow drugs. This may be good for smaller pharma companies like one stock, which was one of Chen Lin's top picks for 2024.
Tags:  Biotechnology / PharmaceuticalsHealthcare Services

Biotech Co.'s Sales Could Grow To US$310 Million in 2028

Research Report
  ()
Biotech Valneva SE announced that it had dosed the first participant in a Phase 2 pediatric trial evaluating its chikungunya vaccine candidate, according to an H.C. Wainwright & Co. report.
Tags:  Biotechnology / Pharmaceuticals

2024: Chen Leads With Biotech After Picking 2023's Top Stock

  ()
Asset manager Chen Lin was very happy with his picks from 2023, including one that ended up soaring 1,900%. See what the asset manager has lined up for the new year.
Tags:  GoldSilverBiotechnology / Pharmaceuticals

Market Correction and One Cash Rich Biotech

Contributed Opinion
  ()
In late December, Ron Struthers pointed out that the S&P 500 made a double top and showed numerous over-bought conditions, so a correction is expected. He also shared one biotech that has been whacked down way below its cash value.
Tags:  Biotechnology / Pharmaceuticals

Boston Biotech Could Have Blockbuster Sales

Research Report
  ()
Tango Therapeutics may have "blockbuster potential," noted an H.C. Wainwright & Co. report.
Tags:  Biotechnology / Pharmaceuticals

Pharma Co. Gets First US Patent for Repurposed Drug

  ()
Clinical-stage pharmaceuticals firm Algernon Pharmaceuticals Inc. has been issued a U.S. patent for the treatment of three related diseases with its investigational drug repirinast.
Tags:  NutraceuticalsPsychedelicsBiotechnology / Pharmaceuticals

California-Based Pharma Co.'s Progress Offers Upside

Research Report
  ()
While H.C. Wainwright & Co. lowered their price target, they still see upside for this pharmaceutical company.
Tags:  Biotechnology / Pharmaceuticals

Co.'s Breast Cancer Therapy Shows Encouraging Activity

Research Report
  ()
BriaCell Therapeutics Corp.'s lead targeted cell therapy, when combined with the PD-1 inhibitor retifanlimab, achieved an exceptional 71% intracranial objective response rate treating brain metastases in advanced breast cancer patients, according to an H.C. Wainwright report.
Tags:  Biotechnology / Pharmaceuticals

Biotech Secures Additional Funding, Extending Cash Runway

Research Report
  ()
Recently, Vera Therapeutics Inc. announced it had further strengthened its balance sheet by drawing down US$25 million in debt, bringing total cash reserves to US$159.9 million, noted H.C. Wainwright & Co.
Tags:  Biotechnology / Pharmaceuticals

Biotech Bolsters ADC Pipeline Through Atreca Asset Buy

Research Report
  ()
Biotech Immunome Inc. recently announced a purchase agreement with Altreca, noted Wedbush.
Tags:  Biotechnology / Pharmaceuticals

US Biotech's Anti-Fungal Wins European Approvals

Research Report
  ()
Recently, Cidara Therapeutics Inc. secured European Commission (EC) approval for its lead anti-fungal candidate Rezafungin to treat invasive candidiasis infections in adults, noted H.C. Wainwright & Co.
Tags:  Biotechnology / Pharmaceuticals

Showing Results: 1 to 25 of 51 Next